Phase II study of osimertinib in patients with non-small cell lung cancer who acquired resistance to afatinib
Not Applicable
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000028166
- Lead Sponsor
- Asahikawa Medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Patients are excluded if they have; 1. Severe concomitant disease. 2. Severe history oh hypersensitivity. 3. Severe heart disease or arrhythmia. 4. Interstitial pneumoniae. 5. Active infection. 6. Active peptic ulcer. 7. Active double cancer. 8. Symptomatic brain metastasis.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method